NCT00146887

Brief Summary

The purpose of the trial is to investigate the accuracy of coronary CT compared to the conventional "gold standard" cardiac catheterization.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2005

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2005

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2005

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 4, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 7, 2005

Completed
Last Updated

November 7, 2006

Status Verified

August 1, 2005

First QC Date

September 4, 2005

Last Update Submit

November 6, 2006

Conditions

Atherosclerosis, Coronary

Keywords

Coronary CTsensitivityspecificity

Outcome Measures

Primary Outcomes (1)

  • CT sensitivity and specificity

Interventions

coronary catheterizationPROCEDURE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who are scheduled to undergo coronary angiogram will be recruited at Mount Scopus and Ein Kerem

You may not qualify if:

  • CABG or stent implantation in the past.
  • Atrial fibrillation
  • Contraindication for beta blockers
  • Obstructive pulmonary disease
  • Severe peripheral vascular disease
  • Sick sinus syndrome or AV block greater than 1st degree.
  • Systolic blood pressure below 100 mm Hg.
  • Renal disease or other conditions that might increase the risk of contrast nephropathy (diabetes mellitus, SLE, paraproteinemia, malignancy, liver disease)
  • Allergy to contrast material.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hadassah Medical Center

Jerusalem, Israel

RECRUITING

MeSH Terms

Conditions

Coronary Artery DiseaseHypersensitivity

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesImmune System Diseases

Study Officials

  • ronen durst, MD

    Hadassah Medical Organization

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ronen Durst, MD

CONTACT

972-2-6777111durst@cc.huji.ac.il

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 4, 2005

First Posted

September 7, 2005

Study Start

January 1, 2005

Study Completion

August 1, 2005

Last Updated

November 7, 2006

Record last verified: 2005-08

Locations

IL(1)